[Leish-l] [Possivel Spam] Cutaneous leishmaniasis treatment evasion

[Kwang-Poo Chang]

I read the articles with great interest, even though the patients appeared
to be travelers who got CL and returned to France and England.

KP

On Fri, Feb 19, 2016 at 12:46 PM, Carlos Costa <chncosta at gmail.com> wrote:

> Dear Bartira,
>
> I fully agree with Pierre.
>
> Cheers,
>
> Carlos.
>
> Em sexta-feira, 19 de fevereiro de 2016, Pierre Buffet <pabuffet at gmail.com>
> escreveu:
>
>> Dear Bartira,
>>
>> please find attached 2 references on this topic that bring contrasted
>> responses to your question (but "selection" criteria were different).
>>
>> In our experience about one third of CL patients treated with antimony
>> and liposomal amphotericin B interrupt their treatment due to systemic side
>> effects of variable severity. Interruption depends on the side effect but
>> also on the indication. I would spend more energy and accept a higher level
>> of risk to treat an immunocompromised  patient with visceral leishmaniasis
>> unresponsive to amphotericin B than an immunocompetent patient with
>> localized CL (most of whom should in my opinion be treated locally).
>>
>> Hope this is helpful.
>>
>> All the best
>>
>> Pierre
>>
>>
>> 2016-02-18 20:35 GMT+01:00 Bartira Rossi Bergmann <bartira at biof.ufrj.br>:
>>
>>> Dear colleagues,
>>>
>>> Does anybody have an idea of the percentage of patients that do not
>>> complete the whole series of injections (overall available injectable
>>> drugs) against cutaneous leishmaniasis - locally or worldwide - due to
>>> adverse side effects?
>>>
>>> Thanks a lot!
>>>
>>> Bartira
>>>
>>>
>>>
>>>
>>> --
>>> Bartira Rossi Bergmann
>>> Professora Associada
>>> Instituto de Biofísica Carlos Chagas Filho
>>> Universidade Federal do Rio de Janeiro - Brasil
>>> tel: +55 (21) 2260-6963
>>> _______________________________________________
>>> Leish-l mailing list
>>> Leish-l at lineu.icb.usp.br
>>> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>>>
>>> --
>>> This email was sent by icb.usp.br
>>>
>>
>>
>>
>> --
>> Pr. Pierre Buffet, MD, PhD
>> Faculté de Médecine Université Paris Descartes
>> Institut National de la Transfusion Sanguine
>> 6 rue Cabanel, 75015 Paris
>> Paris, France
>> Téléphone: +33 (0)6 26 16 68 11
>> pabuffet at gmail.com
>>
>>
>>
>>
>> --
>> * This email was sent by icb.usp.br <http://icb.usp.br> *   ­­
>
>
>
> --
> Carlos H. N. Costa, MD, DSc.
> Coordenador
> Laboratório de Leishmanioses - LabLeish
> Universidade Federal do Piauí
> Instituto de Doenças Tropicais Natan Portella
> Rua Artur de Vasconcelos 151-Sul
> 64001-450 Teresina-PI
> Brazil
> Telephones: +55 86 3222-4377 (W),
> +55 86 3221-3062 (W),
> +55 86 3237-1075 (R).
>
>
> Aviso: As informações contidas nesta mensagem são CONFIDENCIAIS,
> protegidas pelo sigilo legal, por direitos autorais e destinadas
> exclusivamente à pessoa ou organização para a qual a mensagem foi destinada.
> Warning: This message is meant only for the intended recipient of the
> transmission.  It is forbidden any unauthorized use, alteration,
> reproduction and distribution. If you are not the correct recipient, please
> notify us immediately by return e-mail and delete this message from your
> system.
>
>
>
> --
> * This email was sent by icb.usp.br <http://icb.usp.br> *   ­­
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>
> --
> This email was sent by icb.usp.br
>
>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20160219/7dd23232/attachment-0001.htm>